256 patient-derived organoids from colorectal, oesophageal, ovarian, pancreatic and gastric cancers were established as a renewable, clinically annotated biobank, with matched genome and transcriptome data and public access through repositories and databases.
162 of those organoids passed genome-wide CRISPR-Cas9 screening, letting researchers chart cancer dependencies at scale and identify 1,841 significant gene-biomarker links, including subtype-specific vulnerabilities and 97 core fitness genes not seen in cell-line maps.
171 organoid-tumour pairs showed strong genomic fidelity, with high correlations for mutational load, structural variants and copy-number profiles, supporting the models as closer patient-linked complements to conventional cancer cell lines.
Colorectal analyses found EGFR-RAS-MAPK dependence varied by KRAS allele: G12X models were more dependent on KRAS and EGFR, while a Q61H model resisted EGFR withdrawal and EGFR inhibitors.
Paired pre- and post-treatment oesophageal organoids also captured tumour evolution after chemotherapy, revealing shifts in druggable dependencies that altered sensitivity to pan-RAS, DNMT1 and proteasome inhibitors.
Only 256 of 907 cancer samples survived as organoids; does this biological bias hide the deadliest tumor secrets?
If 3D organoids expose hidden cancer vulnerabilities, could this biobank finally outsmart therapy-resistant tumors?
The 256-Organoid Biobank: Transforming Cancer Research and Precision Medicine with Patient-Derived 3D Models
Overview
The launch of the 256-organoid biobank marks a major advance in cancer research by overcoming the limitations of traditional 2D cell lines, which fail to mimic the complexity of real tumors and often lead to failed clinical trials. Patient-derived organoids (PDOs) retain patient-specific traits in 3D, providing more accurate drug testing and reducing the gap between lab research and patient care. By mapping genetic vulnerabilities through CRISPR screens, the biobank helps identify new drug targets. Open-access data, standardized protocols, and improved consent for commercial use further accelerate clinical translation, while ongoing efforts address technical, legal, and ethical challenges.